Onyvax - oncology vaccines
  About Onyvax  


VaxOnco Inc, a Korean speciality biotechnology company, has acquired all of the intellectual property relating to Onyvax-P.

All further development of Onyvax's products will be conducted through VaxOnco.

Clinical Trials Science

Sep 1, 2009
VaxOnco Inc announces acquisition of rights to Onyvax-P cell vaccine

Careers Press Releases


For up to date information about the Onyvax prostate cancer vaccine, please contact KAEL-GemVax (formerly VaxOnco) of Seoul Korea.

Members of the Onyvax executive team can be contacted through Alacrita, a specialist pharmaceutical management consulting firm.